Sweet L
24.3K posts

Sweet L
@lareux24
Father, husband, user of common sense, seeker of knowledge, answers, and truth, fan of sarcasm

BREAKING: Partial internet has been restored to Iran, with videos finally coming out showing the extent of protests against the regime. Millions demanded an end to the Mullahs.

BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal 84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION. Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995. The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology. A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole. Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability. At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either: No evidence of disease (32.8%) Tumor regression (15.6%) or Cancer stabilization (36.1%) Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months. Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments. This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential. With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required. In the meantime, many cancer patients are exercising their right to try. @twc_health @McCulloughFund @IIAR_Journals @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson





The main stream news is failing to do their job, so here is the bigger picture on this story out of NH. The man pretending to be a woman hanging out in women and children's private spaces is Christopher Beaulieu. He was previously convicted of felonious sexual assault (victim was a minor). So the thing they say never happens is absolutely happening. He also hangs out at Chuck E Cheese in Manchester. Judy Walcott was getting ready to use the bathroom in the women’s locker room at the Concord Planet Fitness when she saw Christopher hanging up belongings outside a shower. Understandably she was very uncomfortable and scared (I know this feeling because men use our restrooms in the State House too), so she went to the front desk and reported it. The employees ignored it. A few days later, she reported it to another employee who called her “transphobic” and told her to quit if she didn’t like it. A few hours later, the assistant manager called her and canceled the membership. They forged her signature on the cancelation too. This smells like a lawsuit waiting to happen. So a woman was punished for being frightened in her private space, and the man is still hanging out freely in there. @KellyAyotte help! @libsoftiktok














The Israel lobby takes out Thomas Massie and kills MAGA in the process. The good news is, we’ve now confirmed how the system works.











